Mga Batayang Estadistika
| CIK | 1787306 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Arcutis Biotherapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTHE |
|
| August 6, 2025 |
Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update •Q2 2025 net product revenue for ZORYVE® (roflumilast) was $81. |
|
| August 6, 2025 |
, by and between the Registrant and Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. MANUFACTURING SUPPLY AGREEMENT This Manufacturing Supply Agreement (the “Agreement”), dated as of November 8, 2023 (the “Effective Date”), is entered into by |
|
| August 6, 2025 |
Amendment No. 1 to the Manufacturing Supply Agreement, dated as of Exhibit 10.2 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. AMENDMENT 1 to the MANUFACTURING SUPPLY AGREEMENT This Amendment (this “Amendment”) is entered into as of March 22, 2024 (“Amendment Effective Date”) between |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Commi |
|
| August 6, 2025 |
, by and between the Registrant and Bora Pharmaceuticals Services Exhibit 10.3 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. AMENDMENT 2 to the MANUFACTURING SUPPLY AGREEMENT This Amendment (this “Amendment”) is entered into as of May 14, 2025 (“Amendment Effective Date”) between Ar |
|
| June 17, 2025 |
Amended and Restated Non-Employee Director Exhibit 10.1 ARCUTIS BIOTHERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM This Arcutis Biotherapeutics, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2020 Equity Incentive Plan (the “Plan”) and shall be effective, as amended and restated herein, as of June 11, 2025 (the “Effective Date”). Capitalized terms not othe |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Commis |
|
| May 6, 2025 |
Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update •Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63. |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTH |
|
| May 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Commissi |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy St |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy S |
|
| April 10, 2025 |
Arcutis Announces Chief Financial Officer Transition FOR IMMEDIATE RELEASE Arcutis Announces Chief Financial Officer Transition WESTLAKE VILLAGE, CA, April 10, 2025 – Arcutis Biotherapeutics, Inc. |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2025 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Commi |
|
| April 10, 2025 |
Severance & Change in Control Agreement, dated ARCUTIS BIOTHERAPEUTICS, INC. SEVERANCE & CHANGE IN CONTROL AGREEMENT This Severance & Change in Control Agreement (the “Agreement”) is entered into by and between Latha Vairavan (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware company (the “Company”), effective as of the date of the Executive’s promotion to a Senior Vice President of the Company (the “Effective Date”). 1.Term of Ag |
|
| February 25, 2025 |
Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update •Q4 2024 net product revenue for ZORYVE® (roflumilast) was $69. |
|
| February 25, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Arcutis Biotherapeutics, Inc. |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Co |
|
| February 25, 2025 |
As filed with the Securities and Exchange Commission on February 25, 2025 As filed with the Securities and Exchange Commission on February 25, 2025 Registration No. |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTHERAPE |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2025 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Com |
|
| January 13, 2025 |
3027 Townsgate Road, Suite 300 Westlake Village, CA 91361 | arcutis.com Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million •Preliminary unaudited product revenue for the fourth quarter of 2024 is expected to be approximately $63 million, up approximately 366% vs. |
|
| November 14, 2024 |
SC 13G/A 1 p24-3171sc13ga.htm ARCUTIS BIOTHERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Arcutis Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03969K108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of th |
|
| November 13, 2024 |
ARQT / Arcutis Biotherapeutics, Inc. / Rubric Capital Management LP - SC 13G/A Passive Investment SC 13G/A 1 tm2427812d3sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Arcutis Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 03969K108 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the appr |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS B |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Com |
|
| November 6, 2024 |
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update •Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44. |
|
| August 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Comm |
|
| August 14, 2024 |
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update •Second quarter net product revenues for ZORYVE® franchise of $30. |
|
| August 14, 2024 |
Execution Version SECOND AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of August 9, 2024, by and among SLR INVESTMENT CORP. |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTHE |
|
| July 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission Fi |
|
| June 18, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Commis |
|
| May 14, 2024 |
Exhibit 10.3 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is the type that the registrant treats as private or confidential. LICENSE AGREEMENT by and between Arcutis Biotherapeutics, Inc., and Sato Pharmaceutical Co., Ltd. Dated as of February 27, 2024 i TABLE OF CONTENTS ARTICLE 1 DEFINITION |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTH |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Commiss |
|
| May 14, 2024 |
, 2024, by and between the Registrant and Hangzhou Zhongmei Hua Exhibit 10.4 FIRST AMENDMENT TO THE LICENSE AGREEMENT THIS FIRST AMENDMENT TO THE LICENSE AGREEMENT (this “Amendment”) is made as of [●], 2024 (the “Amendment Effective Date”), by and between Arcutis Biotherapeutics, Inc. (“Arcutis”) and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd (“Huadong”). Capitalized terms used herein but not defined herein shall have the same meaning as set forth in th |
|
| May 14, 2024 |
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update •First quarter net product revenues for ZORYVE® franchise of $21. |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy S |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy St |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2024 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Commi |
|
| April 10, 2024 |
ffer Letter of Employment Agreement, dated 3027 TOWNSGATE ROAD • SUITE 300 WESTLAKE VILLAGE • CA • 91361 805-418-5006 • WWW.ARCUTIS.COM Exhibit 10.1 April 5, 2024 David Topper RE: Employment with Arcutis Biotherapeutics, Inc. Dear David: This employment letter sets forth the terms and confirms your employment as Senior Vice President and Chief Financial Officer with Arcutis Biotherapeutics, Inc., a Delaware Corporation (the “Company” or “A |
|
| April 10, 2024 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Arcutis Appoints David Topper as Chief Financial Officer • Industry veteran with over 40 years of experience in finance, investment management, and investment banking WESTLAKE VILLAGE, Calif., April 10, 2024 – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno- dermatology, today announc |
|
| April 10, 2024 |
Severance and Change in Control Agreement, dated April 5, 2024, by and between the Registra Exhibit 10.2 ARCUTIS BIOTHERAPEUTICS, INC. SEVERANCE & CHANGE IN CONTROL AGREEMENT This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between David Topper (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware company (the “Company”), and is effective as of the date that this Agreement is signed (the “Effective Date”). 1. TERM OF AGREEMENT. This Agreeme |
|
| March 6, 2024 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6)* Arcutis Biotherapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03969K 108 (CUSIP Number) Steve R. Bailey 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Address and Telephone Number of |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Co |
|
| March 4, 2024 |
Exhibit 1.1 Arcutis Biotherapeutics, Inc. Common Stock, Par Value $0.0001 per Share Underwriting Agreement February 28, 2024 Morgan Stanley & Co. LLC Cowen and Company, LLC Guggenheim Securities, LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Cowen and Company, LLC 599 Le |
|
| March 1, 2024 |
15,789,474 Shares Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-276794 PROSPECTUS SUPPLEMENT (to Prospectus dated February 8, 2024) 15,789,474 Shares Common Stock We are offering 15,789,474 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “ARQT.” On February 27, 2024, the last reported sale price of our common stock on the Nasdaq Global Select Market |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Co |
|
| February 28, 2024 |
SUBJECT TO COMPLETION, DATED FEBRUARY 28, 2024 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| February 27, 2024 |
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update •Q4 net product revenues for ZORYVE® (roflumilast) cream 0. |
|
| February 27, 2024 |
Insider Trading Policy and Procedures Insider Trading Policy and Procedures Introduction Federal and state laws prohibit trading in the securities of a company while in possession of material nonpublic information and in breach of a duty of trust or confidence. |
|
| February 27, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Arcutis Biotherapeutics, Inc. |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTHERAPE |
|
| February 27, 2024 |
As filed with the Securities and Exchange Commission on February 27, 2024 As filed with the Securities and Exchange Commission on February 27, 2024 Registration No. |
|
| February 27, 2024 |
Exhibit 10.35 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment (“Amendment”) to the Employment Agreement (“Employment Agreement”) by and between Arcutis Biotherapeutics, Inc., a Delaware corporation (the “Company”) and Matthew R. Moore (the “Executive”) dated as of December 18, 2020, is entered into by the Company and the Executive on, and to be effective as of February 22, 2024. Capitalized terms |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Co |
|
| February 27, 2024 |
Arcutis Biotherapeutics, Inc. Policy for Reco Exhibit 19 ARCUTIS BIOTHERAPEUTICS, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Arcutis Biotherapeutics, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of December 1, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Su |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2024 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Co |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) ARCUTIS BIOTHERAPEUTICS, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 03969K108 (CUSI |
|
| February 14, 2024 |
ARQT / Arcutis Biotherapeutics, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment SC 13G/A 1 arcu.htm DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment # 1 Name of Issuer: ARCUTIS BIOTHERAPEUTICS INC Title of Class of Securities: Common Stock CUSIP Number: 03969K108 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER OF A GR |
|
| February 13, 2024 |
ARQT / Arcutis Biotherapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv0325-arcutisbiotherapeutic.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Arcutis Biotherapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 03969K108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule |
|
| February 13, 2024 |
ARQT / Arcutis Biotherapeutics, Inc. / Polar Capital Holdings Plc Passive Investment SC 13G/A 1 polar-arqt123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. )* ARCUTIS BIOTHERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03969K108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| February 13, 2024 |
ARQT / Arcutis Biotherapeutics, Inc. / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment SC 13G/A 1 d1096356313g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Arcutis Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03969K108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| February 12, 2024 |
ARQT / Arcutis Biotherapeutics, Inc. / Rubric Capital Management LP - SC 13G Passive Investment SC 13G 1 tm245464d2sc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Arcutis Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 03969K108 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate bo |
|
| February 8, 2024 |
ARCUTIS BIOTHERAPEUTICS, INC. Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-276794 PROSPECTUS ARCUTIS BIOTHERAPEUTICS, INC. $100,000,000 Common Stock We have entered into an amended and restated sales agreement, or the Sales Agreement, with TD Cowen, relating to shares of our common stock offered by this prospectus. In accordance with the terms of such Sales Agreement, we may offer and sell shares of our common stock h |
|
| February 6, 2024 |
Arcutis Biotherapeutics, Inc. 3027 Townsgate Road, Suite 300 Westlake Village, California 91361 Arcutis Biotherapeutics, Inc. 3027 Townsgate Road, Suite 300 Westlake Village, California 91361 February 6, 2024 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Alan Campbell Re: Arcutis Biotherapeutics, Inc. Registration Statement on Form S-3 (Registration No. 33 |
|
| January 31, 2024 |
Exhibit 4.5 Arcutis Biotherapeutics, Inc INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 5 Section 1.4. Rules of Construction. 5 ARTICLE II. THE SECURITIES 6 Section 2.1. Issuable in Series. 6 Section 2.2. |
|
| January 31, 2024 |
SC 13G 1 p24-0547sc13g.htm ARCUTIS BIOTHERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Arcutis Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03969K108 (CUSIP Number) January 30, 2024 (Date of Event Which Requires Filing of this State |
|
| January 31, 2024 |
As filed with the Securities and Exchange Commission on January 31, 2024 As filed with the Securities and Exchange Commission on January 31, 2024 Registration No. |
|
| January 31, 2024 |
Amended and Restated Sales Agreement, dated January 31, 2024, by and between Exhibit 1.2 Execution Version ARCUTIS BIOTHERAPEUTICS, INC. $100,000,000 SHARES OF COMMON STOCK PAR VALUE $0.0001 PER SHARE AMENDED AND RESTATED SALES AGREEMENT January 31, 2024 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Reference is made to that certain Sales Agreement, entered into as of May 6, 2021 (the “Original Sales Agreement”), by and between Arcuti |
|
| January 31, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Arcutis Biotherapeutics, Inc. |
|
| January 31, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p24-0547exhibit99.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing a |
|
| January 24, 2024 |
650 Town Center Drive, 20th Floor Costa Mesa, California 92626-1925 Tel: +1.714.540.1235 Fax: +1.714.755.8290 www.lw.com FIRM / AFFILIATE OFFICES Austin Milan Beijing Munich Boston New York Brussels Orange County Century City Paris Chicago Riyadh Dubai San Diego Düsseldorf San Francisco Frankfurt Seoul Hamburg Silicon Valley Hong Kong Singapore Houston Tel Aviv London Tokyo Los Angeles Washington, |
|
| January 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) ARCUTIS BIOTHERAPEUTICS, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 03969K108 (CUSI |
|
| January 16, 2024 |
Screenshots of Option Exchange Website Exhibit (a)(1)(vi) HOME DOCUMENT LIBRARY MY OPTIONS LOG OUT Welcome! You have one or more outstanding option grants that are eligible to be exchanged under the Arcutis Biotherapeutics, Inc. |
|
| January 16, 2024 |
Form of Reminder Email Communications Exhibit a(1)(v) Subject: Reminder – Arcutis Option Exchange Program Closes Soon As an eligible participant, in Arcutis Option Exchange Program to Exchange Eligible Options for New Restricted Stock Units (RSUs), we are pleased to inform you that the Option Exchange is still open and you have time to make an election until the Option Exchange expires at 8:59 p. |
|
| January 16, 2024 |
Form of Initial Email Communication Exhibit (a)(1)(ii) Subject: Arcutis Option Exchange Program Now Open We are pleased to announce that Arcutis Option Exchange Program opens today! You are receiving this email because you have the opportunity to exchange your underwater options for a smaller number of new Restricted Stock Units (RSUs) through the end of the current option exchange period, expiring on 2/12/2024. |
|
| January 16, 2024 |
Offer to Exchange Certain Outstanding Stock Options for Restricted Stock Units, dated January Exhibit (a)(1)(i) ARCUTIS BIOTHERAPEUTICS, INC. OFFER TO EXCHANGE CERTAIN OUTSTANDING OPTIONS TO PURCHASE SHARES OF COMMON STOCK FOR REPLACEMENT RSU AWARDS SUMMARY TERM SHEET – OVERVIEW THIS OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 8:59 P.M. PACIFIC TIME ON FEBRUARY 12, 2024 UNLESS THIS OFFER IS EXTENDED Arcutis Biotherapeutics, Inc. which is sometimes referred to herein as the “Company,” “Arcutis,” |
|
| January 16, 2024 |
Option Exchange Frequently Asked Questions Exhibit (a)(1)(vii) OPTION EXCHANGE FREQUENTLY ASKED QUESTIONS The following are answers to some of the questions that you may have about this Offer. |
|
| January 16, 2024 |
Exhibit (a)(1)(iii) ARCUTIS BIOTHERAPEUTICS, INC. TERMS OF ELECTION BY PARTICIPATING, YOU AGREE TO ALL TERMS OF THE OFFER AS SET FORTH IN THE OFFER TO EXCHANGE CERTAIN OUTSTANDING OPTIONS TO PURCHASE SHARES OF COMMON STOCK FOR REPLACEMENT RESTRICTED STOCK UNIT AWARDS, DATED JANUARY 16, 2024 (AS IT MAY BE AMENDED AND SUPPLEMENTED FROM TIME TO TIME, THE “OFFER TO EXCHANGE”). Arcutis Biotherapeutics, |
|
| January 16, 2024 |
Option Exchange Presentation to Employees and Consultants Stock Option Exchange Program January 2024 1 Agenda • Introductions and Overview • The Basics • How an Option Exchange Works • Eligibility • RSU Terms • Considering Your Choice • Important Disclaimers • Q&A Quick Intro • John Hammond, CEP FGE | Aon Rewards Solutions • 20 + years in stock plan industry • 30 years in employee financial space • 100% focused on employee education – leads Rewards commu |
|
| January 16, 2024 |
Form of Email Confirmation to Eligible Employees and Consultants Exhibit (a)(1)(iv) Subject: Confirmation of Receipt of Option Exchange Election This email is to confirm receipt of the changes to your options through Arcutis Option Exchange Site. |
|
| January 16, 2024 |
Exhibit 107 Calculation of Filing Fee Table SC TO-I (Form Type) Arcutis Biotherapeutics, Inc. |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ARCUTIS BIOTHERAPEUTICS, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 03969K108 (CUSIP Number of Class |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2024 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Com |
|
| January 11, 2024 |
exhibit991-toxc Option Exchange Offer January 11, 2024 • Employees and consultants with stock options will have the opportunity to exchange ‘underwater’ equity grants for restricted stock units (RSUs). |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2024 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Com |
|
| January 11, 2024 |
Communication to Eligible Participants exhibit991-toxc Option Exchange Offer January 11, 2024 • Employees and consultants with stock options will have the opportunity to exchange ‘underwater’ equity grants for restricted stock units (RSUs). |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Co |
|
| November 16, 2023 |
ARQT / Arcutis Biotherapeutics Inc / Polar Capital Holdings Plc Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 9, 2023 |
ARQT / Arcutis Biotherapeutics Inc / PRUDENTIAL FINANCIAL INC Passive Investment SC 13G 1 arcutis.htm DOCUMENT TYPE SC 13G TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Name of Issuer: ARCUTIS BIOTHERAPEUTICS INC Title of Class of Securities: Common Stock CUSIP Number: 03969K108 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER OF A GROUP: (a) N/A (b |
|
| November 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2023 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Com |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS B |
|
| November 3, 2023 |
Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update •Achieved total revenues of $38. |
|
| November 3, 2023 |
First Amendment to Amended and Restated Loan and Security Agreement, dated Exhibit 10.2 Execution Version FIRST AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of November 1, 2023, by and among SLR INVESTMENT CORP., a Maryland corporation with an office located at 500 Park Avenue, 3rd Floor, New York, NY 10022 (“SLR”), as collateral agent (in such |
|
| November 3, 2023 |
Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is the type that the registrant treats as private or confidential. LICENSE AGREEMENT by and between Arcutis Biotherapeutics, Inc., and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd Dated as of August 10, 2023 i TABLE OF CONTENTS AR |
|
| October 30, 2023 |
ARQT / Arcutis Biotherapeutics Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment SC 13G 1 d1085420213-g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Arcutis Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03969K108 (CUSIP Number) October 20, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| October 26, 2023 |
ARQT / Arcutis Biotherapeutics Inc / Frazier Life Sciences VIII, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d517650dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5)* Arcutis Biotherapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03969K 108 (CUSIP Number) Steve R. Bailey 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Ad |
|
| October 23, 2023 |
32,500,000 Shares of Common Stock Pre-Funded Warrants to Purchase 7,500,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-252612 PROSPECTUS SUPPLEMENT (to Prospectus dated February 1, 2021) 32,500,000 Shares of Common Stock Pre-Funded Warrants to Purchase 7,500,000 Shares of Common Stock We are offering 32,500,000 shares of our common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 7,500,000 shares of our common stock. The |
|
| October 23, 2023 |
Exhibit 4.1 ARCUTIS BIOTHERAPEUTICS, INC. FORM OF WARRANT TO PURCHASE COMMON STOCK Warrant No. [l] Number of Shares: [l] (subject to adjustment) Original Issue Date: [l], 2023 Arcutis Biotherapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [l] or its permitted registered |
|
| October 23, 2023 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Arcutis Biotherapeutics, Inc. |
|
| October 23, 2023 |
Exhibit 1.1 Execution Version Arcutis Biotherapeutics, Inc. Common Stock, Par Value $0.0001 per Share Pre-Funded Warrants to Purchase Shares of Common Stock Underwriting Agreement October 19, 2023 Morgan Stanley & Co. LLC Cowen and Company, LLC Guggenheim Securities, LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Morgan Stanley & Co. LLC |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2023 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Com |
|
| October 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2023 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Com |
|
| October 19, 2023 |
Corporate Overview 2©Copyright 2023. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. Legal Disclaimers This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other th |
|
| October 19, 2023 |
SUBJECT TO COMPLETION, DATED OCTOBER 19, 2023 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| September 27, 2023 |
FOR IMMEDIATE RELEASE Arcutis Appoints L. Todd Edwards as Chief Commercial Officer • Industry veteran with deep commercial experience in dermatology and immunology • Ayisha Jeter appointed Senior Vice President, Marketing and Market Access WESTLAKE VILLAGE, Calif., Sep. 27, 2023 – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developin |
|
| September 27, 2023 |
3027 TOWNSGATE ROAD • SUITE 300 WESTLAKE VILLAGE • CA • 91361 805-418-5006 • WWW.ARCUTIS.COM September 16, 2023 L. Todd Edwards RE: Employment with Arcutis Biotherapeutics, Inc. Dear Todd: This employment letter sets forth the terms and confirms your employment as Senior Vice President and Chief Commercial Officer with Arcutis Biotherapeutics, Inc., a Delaware Corporation (the “Company” or “Arcuti |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2023 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (C |
|
| September 27, 2023 |
everance and Change in Control Agreement, dated September 16, 2023, by and between Todd ARCUTIS BIOTHERAPEUTICS, INC. SEVERANCE & CHANGE IN CONTROL AGREEMENT This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between L. Todd Edwards (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware company (the “Company”), and is effective as of the date that this Agreement is signed (the “Effective Date”). 1. TERM OF AGREEMENT. This Agreement shall t |
|
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-3 |
|
| September 15, 2023 |
September 15, 2023 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549 Attn: Ibolya Ignat Mary Mast Re: Comment Letter dated September 8, 2023 Arcutis Biotherapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed February 28, 2023 File No. 001-39186 To the addressees set |
|
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39 |
|
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2023 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Co |
|
| September 7, 2023 |
, 2023, by and between John Smither and the Company. offerofemploymentsmither 3027 TOWNSGATE ROAD • SUITE 300 WESTLAKE VILLAGE • CA • 91361 805-418-5006 • WWW. |
|
| September 7, 2023 |
ber 6, 2023, by and between John Smither and the Registrant Smither CIC Agreement ARCUTIS BIOTHERAPEUTICS, INC. SEVERANCE AND CHANGE IN CONTROL AGREEMENT This Severance and Change in Control Agreement (the “Agreement”), is entered into by and between John Smither (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware company (the “Company”), and is effective as of the date that this Agreement is signed (the “Effective Date”). 1. TERM OF AGREEMENT. |
|
| August 18, 2023 |
DRAFT NOT FOR IMMEDIATE RELEASE Arcutis Appoints Interim Chief Financial Officer (CFO) • Former and First Arcutis CFO, John Smither, Appointed Interim WESTLAKE VILLAGE, Calif. |
|
| August 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2023 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Comm |
|
| August 14, 2023 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Comm |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Commi |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTHE |
|
| August 8, 2023 |
Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update •Achieved total revenues of $5. |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2023 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Commiss |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Commiss |
|
| May 24, 2023 |
Arcutis Announces Leadership Transition FOR IMMEDIATE RELEASE Arcutis Announces Leadership Transition •Senior Vice President and Chief Commercial Officer (CCO) Ken Lock Stepping Down •Ayisha Jeter Appointed Interim CCO WESTLAKE VILLAGE, Calif. |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Commissi |
|
| May 9, 2023 |
Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update •Achieved net revenues of $2. |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTH |
|
| April 18, 2023 |
DEFA14A 1 a2023defa14a.htm DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy S |
|
| February 28, 2023 |
Form of Non-Employee Director RSU Deferral Election Exhibit 10.37 ARCUTIS BIOTHERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM RSU DEFERRAL ELECTION FORM Please complete and return this RSU Deferral Election Form to the [] so that it is received by Arcutis Biotherapeutics, Inc. (the “Company”) on or before the applicable Submission Deadline (defined below) if you intend to defer the issuance of the shares underlying your Annual RSU Awar |
|
| February 28, 2023 |
Non-Employee Director Compensation Program Exhibit 10.36 ARCUTIS BIOTHERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM This Arcutis Biotherapeutics, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2020 Equity Incentive Plan (the “Plan”) and shall be effective, as amended and restated, as of February 22, 2023 (the “Effective Date”). Capitalized terms not otherw |
|
| February 28, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Arcutis Biotherapeutics, Inc. |
|
| February 28, 2023 |
As filed with the Securities and Exchange Commission on February 28, 2023 As filed with the Securities and Exchange Commission on February 28, 2023 Registration No. |
|
| February 28, 2023 |
AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, modified, or supplemented from time to time, this “Agreement”) dated as of January 10, 2023 (the “Amendment Date”) among SLR INVESTMENT CORP. |
|
| February 28, 2023 |
Table of Contents Index to Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Co |
|
| February 28, 2023 |
Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update •Achieved net revenues of $3. |
|
| February 14, 2023 |
SC 13G/A 1 pt7213gaa.htm SCHEDULE 13G/A, AMENDMENT #2 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* (Name of Issuer) Arcutis Biotherapeutics, Inc. ( |
|
| February 14, 2023 |
EX-99.1 2 pt7213gab.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf |
|
| December 16, 2022 |
Corporate Overview 2?Copyright 2022. Arcutis Biotherapeutics, Inc. ? Presentation designed for an investor audience. Legal Disclaimers This presentation and the accompanying oral presentation contain ?forward-looking? statements that are based on our management?s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other th |
|
| December 16, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Co |
|
| November 8, 2022 |
Exhibit 10.2 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is the type of information that the registrant customarily and actually treats as private and confidential. AMENDMENT NO. 1 DATED OCTOBER 5th, 2022 TO THE SUPPLY AGREEMENT DATED NOVEMBER 24, 2020 BETWEEN Parties (1)ARCUTIS BIOTHERAPEUT |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Com |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS B |
|
| November 8, 2022 |
Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is the type that the registrant treats as private or confidential and is not material. SHARE PURCHASE AGREEMENT AMONG ARCUTIS BIOTHERAPEUTICS, INC. DUCENTIS BIOTHERAPEUTICS LTD. SELLERS (AS DEFINED HEREIN) AND SHAREHOLDER REPRESENTATIVE SERVICES LLC, AS S |
|
| November 8, 2022 |
Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update ?Launched ZORYVE? (roflumilast) cream 0. |
|
| September 7, 2022 |
Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd. Exhibit 99.1 Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd. ?Leverages Arcutis? deep dermatology expertise and broad biologics experience to accelerate Ducentis? lead compound, DS-234, in atopic dermatitis ?Lead indication, atopic dermatitis, is a rapidly growing, significantly underserved market with large unmet need ?Checkpoint agonism is a promising emerging pathway for the trea |
|
| September 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2022 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Co |
|
| September 6, 2022 |
Arcutis Announces Appointment of Neha Krishnamohan to Board of Directors Exhibit 1.1 Arcutis Announces Appointment of Neha Krishnamohan to Board of Directors WESTLAKE VILLAGE, Calif., September 2, 2022 - Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that Neha Krishnamohan has been appointed to the Arcutis Board of Directors and as a member of the audit |
|
| September 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2022 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Co |
|
| August 26, 2022 |
ARQT / Arcutis Biotherapeutics Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 6 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Arcutis Biotherapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03969K108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 7 |
|
| August 26, 2022 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated August 24, 2022, with respect to the ordinary shares of Arcutis Biotherapeutics, Inc. |
|
| August 9, 2022 |
ARQT / Arcutis Biotherapeutics Inc / Frazier Life Sciences VIII, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* Arcutis Biotherapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03969K 108 (CUSIP Number) Steve R. Bailey 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Address and Telephone Number of Person Au |
|
| August 8, 2022 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240. |
|
| August 8, 2022 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated August 4, 2022, with respect to the ordinary shares of Arcutis Biotherapeutics, Inc. |
|
| August 8, 2022 |
ARQT / Arcutis Biotherapeutics Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 5 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Arcutis Biotherapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03969K108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 7 |
|
| August 5, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Commi |
|
| August 5, 2022 |
Exhibit 1.1 Execution Version Arcutis Biotherapeutics, Inc. Common Stock, Par Value $0.0001 per Share Underwriting Agreement August 2, 2022 Morgan Stanley & Co. LLC Cowen and Company, LLC Guggenheim Securities, LLC As representatives (the ?Representatives?) of the several Underwriters named in Schedule I hereto, c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Cowen and Comp |
|
| August 4, 2022 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-252612 PROSPECTUS SUPPLEMENT (to Prospectus dated February 1, 2021) 7,500,000 Shares Common Stock We are offering 7,500,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol ?ARQT.? On August 1, 2022, the last reported sale price of our common stock on the Nasdaq Global Select Market was |
|
| August 4, 2022 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Arcutis Biotherapeutics, Inc. |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTHE |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Commi |
|
| August 4, 2022 |
Arcutis Announces Second Quarter 2022 Financial Results and Provides Business Update Arcutis Announces Second Quarter 2022 Financial Results and Provides Business Update ?Received U. |
|
| August 2, 2022 |
Corporate Overview 2©Copyright 2022. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. Legal Disclaimers This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other th |
|
| August 2, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE FDA APPROVES ARCUTIS’ ZORYVE™ (ROFLUMILAST) CREAM 0.3% FOR THE TREATMENT OF PLAQUE PSORIASIS IN INDIVIDUALS AGE 12 AND OLDER •First and only topical PDE4 inhibitor approved for the treatment of plaque psoriasis, including intertriginous psoriasis •Approved for once-daily treatment in mild, moderate, and severe plaque psoriasis with no limitations on duration of u |
|
| August 2, 2022 |
SUBJECT TO COMPLETION, DATED AUGUST 2, 2022 424B5 1 arcutis424b5preliminarypro.htm 424B5 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has become effective under the Securities Act of 1933, as amended. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securiti |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2022 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Commis |
|
| June 28, 2022 |
ARQT / Arcutis Biotherapeutics Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 4 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Arcutis Biotherapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03969K108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 7 |
|
| June 28, 2022 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated June 24, 2022, with respect to the ordinary shares of Arcutis Biotherapeutics, Inc. |
|
| June 9, 2022 |
Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0. |
|
| June 9, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2022 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Commiss |
|
| June 9, 2022 |
STRATUM Phase 3 Seborrheic Dermatitis Topline Data Presentation June 2022 2?Copyright 2022. |
|
| June 2, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Commiss |
|
| May 27, 2022 |
SC 13D/A 1 d354025dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2) ARCUTIS BIOTHERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Commissi |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTH |
|
| May 5, 2022 |
Arcutis Announces First Quarter 2022 Financial Results and Provides Business Update Arcutis Announces First Quarter 2022 Financial Results and Provides Business Update ?Increasing commercial preparations in advance of our Prescription Drug User Fee Act (PDUFA) action date of July 29, 2022 for roflumilast cream for the treatment of plaque psoriasis in adults and adolescents ?Completed enrollment of the sole pivotal Phase 3 trials of roflumilast foam in both seborrheic dermatitis a |
|
| April 19, 2022 |
DEFA14A 1 a2022defa14a.htm DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x???Filed by a party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy S |
|
| April 8, 2022 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated April 6, 2022, with respect to the ordinary shares of Arcutis Biotherapeutics, Inc. |
|
| April 8, 2022 |
ARQT / Arcutis Biotherapeutics Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Arcutis Biotherapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03969K108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 7 |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A Amendment No. 1 (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 |
|
| February 22, 2022 |
2022 Employment Inducement Incentive Plan and forms of award agreements. ARCUTIS BIOTHERAPEUTICS, INC. 2022 EMPLOYMENT INDUCEMENT INCENTIVE PLAN 1.PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible employees whose potential contributions are important to the success of the Company, and any Subsidiaries that exist now or in the future, by offering them an opportunity to participate in the Company?s future performance thro |
|
| February 22, 2022 |
EX-FILING FEES 2 exhibit107-feetable.htm EX-107 Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Arcutis Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price Fee Rat |
|
| February 22, 2022 |
Execution Version LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, modified, or supplemented from time to time, this ?Agreement?) dated as of December 22, 2021 (the ?Effective Date?) among SLR Investment Corp. |
|
| February 22, 2022 |
Table of Contents Index to Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 22, 2022 |
Offer Letter, dated December 13, 2021, by and between the Registrant and Mas Matsuda. December 13, 2021 Masaru Matsuda 5123 Meadows Del Mar San Diego, CA 92130 RE: Employment with Arcutis Biotherapeutics, Inc. |
|
| February 22, 2022 |
Arcutis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Arcutis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update ?Received U. |
|
| February 22, 2022 |
Severance & Change in Control Agreement, by and between the Registrant and Mas Matsuda. Arcutis Biotherapeutics, Inc. Severance & Change in Control Agreement This Severance & Change in Control Agreement (the ?Agreement?), is entered into by and between Masaru Matsuda (the ?Executive?) and Arcutis Biotherapeutics, Inc., a Delaware company (the ?Company?), and is effective as of the date that this Agreement is signed (the ?Effective Date?). 1.Term of Agreement. This Agreement shall ter |
|
| February 22, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2022 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Co |
|
| February 22, 2022 |
As filed with the Securities and Exchange Commission on February 22, 2022 As filed with the Securities and Exchange Commission on February 22, 2022 Registration No. |
|
| February 14, 2022 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* (Name of Issuer) Arcutis Biotherapeutics, Inc. (Title of Class of Securities) Common Stock, Par Value $ |
|
| December 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2021 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Co |
|
| December 23, 2021 |
Arcutis Biotherapeutics Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners WESTLAKE VILLAGE, Calif. |
|
| December 15, 2021 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) Arcutis Biotherapeutics, Inc. (Title of Class of Securities) Common Stock, Par Value $0 |
|
| December 15, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS B |
|
| November 4, 2021 |
Arcutis Announces Third Quarter 2021 Financial Results and Provides Business Update Arcutis Announces Third Quarter 2021 Financial Results and Provides Business Update ?Submitted New Drug Application (NDA) for roflumilast cream for the treatment of plaque psoriasis across the full spectrum of disease ?Initiated single pivotal Phase 3 trial of roflumilast foam in scalp and body psoriasis ?Enrolling pivotal Phase 3 trials of roflumilast cream in atopic dermatitis and roflumilast fo |
|
| November 4, 2021 |
[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Com |
|
| October 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2021 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Comm |
|
| September 28, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2021 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (C |
|
| September 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2021 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Co |
|
| August 5, 2021 |
Arcutis Announces Second Quarter 2021 Financial Results and Provides Business Update Arcutis Announces Second Quarter 2021 Financial Results and Provides Business Update ?Anticipates submission of a New Drug Application (NDA) for topical roflumilast cream as a potential treatment for plaque psoriasis late in the third quarter or early in the fourth quarter of 2021 ?Initiated single pivotal Phase 3 trial of topical roflumilast foam in seborrheic dermatitis, a disease that affects more than 10 million people in the U. |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTHE |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Commi |
|
| June 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2021 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Commiss |
|
| May 12, 2021 |
Amendment No. 3 to Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Arcutis Biotherapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03969K 108 (CUSIP Number) Steve R. Bailey Frazier Healthcare Partners 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (20 |
|
| May 6, 2021 |
Severance & Change in Control Agreement, by and between the Registrant and Scott L. Burrows. Exhibit 10.2 ARCUTIS BIOTHERAPEUTICS, INC. SEVERANCE & CHANGE IN CONTROL AGREEMENT This Severance & Change in Control Agreement (the ?Agreement?), is entered into by and between Scott L. Burrows (the ?Executive?) and Arcutis Biotherapeutics, Inc., a Delaware company (the ?Company?), and is effective as of the date that this Agreement is signed by both parties (the ?Effective Date?). This Agreement |
|
| May 6, 2021 |
CALCULATION OF REGISTRATION FEE Filed pursuant to Rule 424(b)(5) Registration No. 333-252612 CALCULATION OF REGISTRATION FEE Title of each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price Amount of Registration fee(1) Common Stock, $0.0001 par value per share $100,000,000.00 $10,910.00 (1) Calculated in accordance with Rule 457(o) of the Securities Act of 1933, as amended (the ?Securities Act?), bas |
|
| May 6, 2021 |
Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is the type of information that the registrant customarily and actually treats as private and confidential. EXCLUSIVE DISTRIBUTION AGREEMENT This Exclusive Distribution Agreement (the ?Agreement?) is made as of this 8th day of February |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTH |
|
| May 6, 2021 |
Sales Agreement, dated May 6, 2021, by and between the Registrant and Cowen and Company, LLC. Exhibit 10.3 ARCUTIS BIOTHERAPEUTICS, INC. $100,000,000 SHARES OF COMMON STOCK PAR VALUE $0.0001 PER SHARE SALES AGREEMENT May 6, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Arcutis Biotherapeutics, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and |
|
| May 4, 2021 |
Arcutis Announces First Quarter 2021 Financial Results and Provides Business Update Arcutis Announces First Quarter 2021 Financial Results and Provides Business Update ?New Drug Application (NDA) submission for topical roflumilast cream as a potential treatment for plaque psoriasis anticipated in the second half of 2021 ?Positive Phase 3 results for topical roflumilast cream in plaque psoriasis announced in February ?Advancing topical roflumilast foam into Phase 3 development for |
|
| May 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Commissi |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x???Filed by a party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy S |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x???Filed by a party other than the Registrant ?? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy St |
|
| April 23, 2021 |
140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris Dubai Riyadh D?sseldorf San Diego Frankfurt San Francisco Hamburg Seoul Hong Kong Shanghai Houston Silicon Valley London Singapore Los Angeles Tokyo Madrid Washington, D.C. Milan April 23, |
|
| March 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2021 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Commi |
|
| February 16, 2021 |
As filed with the Securities and Exchange Commission on February 16, 2021 Registration No. |
|
| February 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2021 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Co |
|
| February 16, 2021 |
Supply Agreement, dated November 24, 2020, by and between Registrant and Interquim, S.A. Exhibit 10.25 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. SUPPLY AGREEMENT This Supply Agreement (hereinafter referred to as the ?Agreement?) is entered into on the 24th of November, 2020 (hereinafter referred to as |
|
| February 16, 2021 |
Offer Letter, dated December 18, 2020, by and between the Registrant and Matthew R. Moore. Exhibit 10.23 December 18, 2020 Matthew R. Moore [email protected] RE: Employment with Arcutis Biotherapeutics, Inc. Dear Matt: This employment letter sets forth the terms and confirms your employment as Senior Vice President and Chief Business Officer with Arcutis Biotherapeutics, Inc., a Delaware Corporation (the ?Company? or ?Arcutis?). You will report to me, the Company?s Chief Executive |
|
| February 16, 2021 |
Arcutis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Arcutis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update ?NDA submission for topical roflumilast cream as a potential treatment for plaque psoriasis anticipated in the second half of 2021 ?Positive Phase 3 data on topical roflumilast cream in plaque psoriasis reported in February ?Advancing topical roflumilast into Phase 3 programs for atopic dermatitis, seborrheic dermatitis, and scalp psoriasis during 2021 ?Robust pipeline addressing unmet medical needs of over 20 million patients ?Strong financial position with over $470 million in cash, cash equivalents and marketable securities, including the proceeds from recent equity offering, providing cash runway into 2023 Westlake Village, CA, Feb. |
|
| February 16, 2021 |
Severance & Change in Control Agreement, by and between the Registrant and Matthew R. Moore. Exhibit 10.24 Arcutis Biotherapeutics, Inc. Severance & Change in Control Agreement This Severance & Change in Control Agreement (the ?Agreement?), is entered into by and between Matthew R. Moore (the ?Executive?) and Arcutis Biotherapeutics, Inc., a Delaware (the ?Company?), and is effective as of the date that Executive commences employment with the Company (the ?Effective Date?). 1.Term of Agre |
|
| February 16, 2021 |
Table of Contents Index to Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 9, 2021 |
Amendment No. 2 to Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Arcutis Biotherapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03969K 108 (CUSIP Number) Steve R. Bailey Frazier Healthcare Partners 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (20 |
|
| February 9, 2021 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated February 8, 2021, with respect to the ordinary shares of Arcutis Biotherapeutics, Inc. |
|
| February 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Arcutis Biotherapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03969K108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 7 |
|
| February 9, 2021 |
Arcutis Biotherapeutics, Inc. Form of Orbimed Lock-Up Agreement _____________, 2021 Arcutis Biotherapeutics, Inc. Form of Orbimed Lock-Up Agreement , 2021 Morgan Stanley & Co. LLC, and Cowen and Company, LLC Guggenheim Securities, LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, NY 10036 c/o Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 c/o Guggenheim Securities, LLC 330 Madison Avenue New York, NY 10017 Re: Arcutis Biotherapeutics, Inc. - Lock-Up Agreeme |
|
| February 8, 2021 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240. |
|
| February 5, 2021 |
Exhibit 1.1 Arcutis Biotherapeutics, Inc. Common Stock, Par Value $0.0001 per Share Underwriting Agreement February 2, 2021 Morgan Stanley & Co. LLC Cowen and Company, LLC Guggenheim Securities, LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Cowen and Company, LLC 599 Lex |
|
| February 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2021 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Com |
|
| February 4, 2021 |
CALCULATION OF REGISTRATION FEE Filed Pursuant to Rule 424(b)(5) Registration No. 333-252612 CALCULATION OF REGISTRATION FEE Title of each Class of Securities to be Registered Amount to be Registered(1) Maximum offering price per share(2) Maximum aggregate offering price Amount of Registration fee Common Stock, $0.0001 par value per share 6,325,000 $35.00 $221,375,000 $24,153 (1)Includes 825,000 shares of common stock that the u |
|
| February 1, 2021 |
As filed with the Securities and Exchange Commission on February 1, 2021 Registration No. |
|
| February 1, 2021 |
SUBJECT TO COMPLETION, DATED FEBRUARY 1, 2021 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| February 1, 2021 |
exhibit991-8xk DERMIS-1/DERMIS-2 Phase 3 Plaque Psoriasis Topline Data Review February 2021 Legal Disclaimers This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. |
|
| February 1, 2021 |
Exhibit 4.5 Arcutis Biotherapeutics, Inc. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 3 Section 1.3. Incorporation by Reference of Trust Indenture Act. 4 Section 1.4. Rules of Construction. 4 ARTICLE II. THE SECURITIES 4 Section 2.1. Issuable in Series. 4 Section 2. |
|
| February 1, 2021 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2021 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Com |
|
| January 15, 2021 |
Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2020 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Co |
|
| November 23, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2020 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Co |
|
| November 23, 2020 |
EX-99.1 Exhibit 99.1 Arcutis Announces Positive Topline Data from Phase 2b Study of ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp and Body Psoriasis • Roflumilast foam demonstrated statistically significant improvement on the trial’s primary and multiple secondary endpoints • Once-daily roflumilast foam demonstrated a favorable safety and tolerability profile • Roflumilast |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Com |
|
| November 5, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 0 |
|
| November 5, 2020 |
Arcutis Announces Third Quarter 2020 Financial Results and Provides Business Update Arcutis Announces Third Quarter 2020 Financial Results and Provides Business Update •Pivotal Phase 3 data in plaque psoriasis anticipated in first quarter of 2021 •Pivotal Phase 3 trials in atopic dermatitis anticipated to begin in late 2020 or early 2021 •Recent positive Phase 2 data in seborrheic dermatitis supports pipeline advancement in indication that impacts 10 million patients in the U. |
|
| November 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2020 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39186 81-2974255 (State or other jurisdiction of incorporation) (Com |
